RAF1 and chronic myelogenous leukemia, BCR-ABL1 positive: GRB10 interacts with oncogenic Bcr-Abl in chronic myelogenous leukemia [48], and with active Raf-1 to promote cell survival [49], and it also binds with FLT3 to enhance AML cell proliferation [47], which is suggestive of oncogenicity.